Ask AI
ProCE Banner Activity

CE

Safety Considerations for IV Push Amid Drug Shortages (Enduring Webinar)

Video

Safety Considerations for IV Push Amid Drug Shortages

Pharmacists: maximum of 1.50 contact hours

Pharmacy Technicians: maximum of 1.50 contact hours

Released: January 28, 2026

Expiration: January 28, 2027

Continue Activity

Share

Acknowledgement

This activity is supported by an independent educational grant from Baxter Healthcare Corporation

Provider Statement

This activity is jointly provided by Partners for Advancing Clinical Education (Partners) and the Institute for Safe Medication Practices (ISMP)

Target Audience

Pharmacists, Pharmacy Technicians

Learning Objectives

  • Identify potential risks and adverse drug events associated with IV push medication preparation and administration, especially during IV fluid shortages

  • Review safe practice guidelines and system-level strategies to prevent medication errors and promote safe IV push administration

  • Describe safe implementation of IV push therapies

  • Identify safe implementation practices for IV push therapy by the interprofessional team

Disclosure

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Rita K. Jew, faculty for this activity, has publicly traded stocks: Biogen, Arrowhead Pharmaceuticals, Cencora, Gilead, Glaxo Smith Kline, Novavax, TeleDoc, VaxArt, Vikings Therapeutics

Jana O’Hara, faculty for this activity, has no relevant financial relationships.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Instructions for Credit

  1. There are no fees for participating in and receiving CE credit for this activity.
  2. During the period January 28, 2026 through January 28, 2028, participants must read the educational objectives and faculty disclosures and study the educational activity.
  3. Successfully complete activity post-test with a score of 60% or better and the online evaluation.
  4. Pharmacists/Technicians: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Estimated time to complete activity: 1.5 hours